
Opinion|Videos|July 16, 2026
Differentiating Revumenib and Ziftomenib: Label vs Perception
Pharmacists compare revumenib and ziftomenib in AML—QTc thresholds, CYP3A4 interactions, acid suppression limits, and differentiation syndrome monitoring to optimize safety.
Advertisement
Episodes in this series

In this episode, Zepcan compares the actual label data side by side, addressing agent complexity and monitoring requirements. She examines QTc monitoring, CYP3A4 interactions, PPI interactions, and pharmacokinetic profiles to help guide pharmacy practice.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Building the pharmacy of the future — trust, loyalty, and growth
2
Beyond the Transplant Center: IV Therapy in the Community
3
Understanding Axatilimab's Mechanism in the Context of Multiple Lines of Therapy
4
Incorporating Patient-Reported Symptoms into Treatment Plans
5






























































































